Chimerix Inc. (CMRX)

Name: Chimerix Inc. (CMRX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Chimerix Inc. (CMRX)

Stock Card

$8.54

$0.00 (0.00%)

As on 21-Apr-2025 09:30EDT

Market cap

$801 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

6.6

Div. Yield

0 %

Chimerix (CMRX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 8.54 High: 8.54

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1
Debt to Equity

0
Book Value

$--
EPS

$-1
Face value

--
Shares outstanding

93,803,800

10 Years Aggregate

CFO

$-641.89 Mln

EBITDA

$-816.29 Mln

Net Profit

$-775.03 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Chimerix (CMRX)	145.4	0.8	140.6	865.6	20.3	40.9	-14.0
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 21-Apr-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Chimerix (CMRX)	258.7	-48.4	-71.1	33.1	137.9	-21.0	-44.3
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Chimerix (CMRX)

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage... development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis that is a medical countermeasure for smallpox. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. As of April 17, 2025, Chimerix, Inc. operates as a subsidiary of Jazz Pharmaceuticals plc. Read more

CEO, President & Director

Mr. Michael T. Andriole M.B.A.
CEO, President & Director

Mr. Michael T. Andriole M.B.A.
Headquarters

Durham, NC
Website

https://www.chimerix.com

FAQs for Chimerix (CMRX)

What is the current share price of Chimerix Inc (CMRX) Today?

The share price of Chimerix Inc (CMRX) is $8.54 (NASDAQ) as of 21-Apr-2025 09:30 EDT. Chimerix Inc (CMRX) has given a return of 20.26% in the last 3 years.

What is the current PB & PE ratio of Chimerix Inc (CMRX)?

Since, TTM earnings of Chimerix Inc (CMRX) is negative, P/E ratio is not available.
The P/B ratio of Chimerix Inc (CMRX) is 6.58 times as on 21-Apr-2025, a 27 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.